Human papilloma virus (HPV) is the major cause of cervical cancer. Use of HPV genotyping in cervical screening programs and for monitoring the effectiveness of HPV vaccination programs requires access to economical, high-throughput technology.
Genotyping of HPV infections is important, because different HPV genotypes confer distinctly different risks for development of cervical disease (5 ) . The addition of HPV testing to cytology in primary screening produces a higher sensitivity for the detection of CIN than cytology alone (6, 7 ) . A knowledge of the prevalence and associated risks for each specific HPV genotype also has been essential for the development of vaccines against HPV. High-throughput HPV genotyping will be essential not only for cervicalscreening programs but also for monitoring the effectiveness of HPV vaccination programs, i. e., for documenting decreasing prevalence of the HPV types for which vaccines are available and possibly for changing the occurrence of HPV types without vaccines via type replacement or cross-protection (8 ) .
Although several primarily PCR-based methods have been used to type HPV (9 ) , the massive scale of the monitoring and primary-screening efforts likely to be launched in the near future will require more efficient methods. In the present study, we developed a high-throughput multiplex analysis of 14 distinct HPV high-risk genotypes on the Sequenom MassARRAY matrix-assisted laser desorption/ionization time-offlight (MALDI-TOF) mass spectrometry (MS) system. We compared its performance with that of another method for HPV genotyping, reverse dot blot hybridization (RDBH) of PCR amplimers, as well as with histopathologic diagnoses.
Materials and Methods

STUDY POPULATION
We obtained samples from 271 patients, ages 23-81 years (mean, 38 years; median, 36 years), who were referred to the Department of Gynecology, Västerås Hospital, Västerås, Sweden, for colposcopy after an atypical cervical smear, as described (10 ) . A sample of cervical cells for cytologic and HPV testing and a colposcopy-guided tissue biopsy sample were obtained from all consenting patients. Patients testing positive by at least 2 of the criteria (initial cytology results ՆCIN I, biopsy results ՆCIN I, or abnormal colposcopy results) were treated with loop or laser conization (n ϭ 199). All patients were invited to follow-up visits at 4 -6 months and 16 -18 months after treatment, whether they received treatment or not, and 261 new samples of cervical cells were obtained for cytologic and HPV testing, for a total of 532 samples. The study was approved by the ethics review board of Västerås Hospital.
SAMPLE PREPARATION
Cervical cells were suspended in 1 mL 154 mmol/L NaCl and stored at -20°C. After thawing, the cells were centrifuged at 3 000g for 10 min, and pellets were resuspended in 1 mL 10 mmol/L Tris-HCl, pH 7.4. Before RDBH analysis, 100-L aliquots were freeze-thawed and boiled for 10 min to release the DNA.
After storage at -80°C for 3-6 years, 40-L aliquots of the same 532 DNA extracts were dried in 96-well plates at 37°C overnight and resuspended in 8 L sterile water; 2 L of this suspension was used as template in the primary PCR reaction of the MS method.
To evaluate the sensitivities of the 2 methods, we used standard 10-fold dilution series of 1-1 000 plasmids/reaction with type-specific inserts of each target HPV type and 1-1 000 copies/reaction of DNA extracted from SiHa cells (a cervical cancer cell line containing 1 copy of HPV 16 DNA per cell; American Type Culture Collection).
COMPARISON METHOD
GP5ϩ/6ϩ consensus primers (11 ) and BGPCO5/ BGPCO3 primers (12 ) were used to amplify HPV DNA and the human ␤-globin gene (HBB), respectively, in separate 50-L PCR reaction mixes, each containing 10 L DNA solution as template. The presence of any of the 14 target HPV types or HBB DNA in 5-L aliquots of PCR product was detected by enzyme immunoassay (13 ) . Samples positive for HPV (n ϭ 260) in the enzyme immunoassay were further tested by RDBH (10, 14 ) for the specific HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
MASS SPECTROMETRY
The MS method involves a multiplex primary PCR, in this case with several HPV primers, followed by a homogeneous mass extend (hME) reaction with a single primer of distinct mass that is specific for each genotype. Subsequently, unextended primers demonstrate the absence and specifically extended primers verify the presence and identity of each specific genotype. After laser deionization, the time of flight, which increases with the m/z, is detected for each hME primer. Unless otherwise specified, all procedures were performed with protocols and materials from Sequenom.
PRIMER DESIGN
For the primary PCR, we used Oligo 6.0 software (Cambio) to modify the design of GP5ϩ/6ϩ consensus primers to provide optimal annealing to the 14 target HPV types ( 
a The 10-base 5Ј extension is indicated in underlined lowercase letters. Nucleotides that differ from GP5ϩ/6ϩ primers are in bold type and underlined.
(HPV 33, 35, 58). The number of mismatches was minimized, and A-C mismatches were avoided. All primers have the 5Ј 10-base extension recommended by Sequenom to improve annealing stability in multiplex PCR reactions (see Table 1 ). PCR programs were optimized, and products were viewed after agarose gel electrophoresis. The 14 unique HPV type-specific hME primers are shown in Table 2 . 
hME REACTION
The hME reaction mix was added to the dephosphorylated primary PCR reaction mix and included 1 mol/L of each hME primer (Table 2) , 0.229 L terminator mix (Sequenom) containing equal amounts of dATP, dCTP, ddGTP, and ddTTP, and 1.25 U Thermo Sequenase (Sequenom) in a final volume of 10 l. The PCR program was 94°C for 2 min, followed by 99 cycles of 94°C for 5 s, 42°C for 10 s, and 72°C for 5 s. After desalting by the addition of 6 mg Clean Resin (item #08040, Sequenom) to each 384-well plate, we applied 15 nL of each hME product to a 384-spot SpectroChip (Sequenom). MS analysis was performed and interpreted with MassARRAY Typer software (Sequenom).
DISCREPANCY BETWEEN METHODS
Seventy-eight samples showed genotypic discrepancies between the RDBH and MS results. For these samples, we purified DNA from 100-L aliquots of the original cell suspension in 10 mmol/L Tris-HCl by proteinase K digestion and DNA precipitation (15 ) . The dried pellets were dissolved in 20 L sterile water. The presence of human DNA in these samples was demonstrated by real-time PCR analysis on a 7900HT instrument (Applied Biosystems) with primers and probes for the human F2 5 gene [coagulation factor II (thrombin)] (C 8726802; Applied Biosystems). Samples testing negative for human DNA (n ϭ 26) were considered not evaluable and were excluded. All 52 samples positive for human DNA were reanalyzed at least once by the MS method. Fluctuating results for specific genotypes in a few samples were apparently due to viral dosage effects. Of the 52 samples, 39 had 1 or more HPV genotypes detected with the RDBH method than were detected with the MS method, 8 had 1 or more HPV genotypes detected with the MS method than were detected with the RDBH method, and 5 had 1 discrepant HPV genotype detected with each method before the MS reanalysis. These 52 samples with persisting discrepancies between the RDBH and MS results were reanalyzed by RDBH with the GP5ϩ/6ϩ primers.
After reanalysis with MS and RDBH, discrepant results remained for 24 samples, of which 10 had been positive for a single HPV type. After a new PCR reaction, these 10 samples were sequenced with the same mix of forward primers as in the primary PCR ( Table 1 ). The presence of HPV found only in the MS method for 6 samples was verified by DNA sequencing. In 4 other cases [none with the diagnosis CIN I or higher (CIN Iϩ)], DNA sequencing was inconclusive. These 4 samples were considered not evaluable and were excluded, for a final total of 502 samples.
STATISTICAL METHODS
Sensitivity, specificity, and positive predictive value were calculated for each method separately regarding the detection of HPV in comparison with histopathologic diagnosis. The concordance between the RDBH and MS methods for the detection of each of the 14 HPV types in all 502 evaluable samples was calculated by means of statistics (16 ) .
Results
Analysis of the dilution series of plasmids revealed the following detection limits per PCR reaction for the MS method: 1 copy for HPV types 16, 52, 58, 59, and 66; 10 copies for HPV types 18, 33, 35, 45, 51, 56, and 68; and 100 copies for HPV types 31 and 39. The detection limits per PCR reaction for the comparison method (RDBH) were as follows: 1 copy for HPV types 16, 51, 58, and 66; 10 copies for HPV types 18, 31, 33, 39, 45, and 56; 100 copies for HPV types 35, 52, and 59; and 1 000 copies for HPV 68. With CIN II or higher (CIN IIϩ) in the histopathologic results as a clinical reference, the sensitivity for the MS method was 91.4% [95% confidence interval (CI), 84.3%-95.6%], the specificity was 46.0% (95% CI, 37.5%-54.7%), and the positive predictive value was 58.9%, whereas the sensitivity of the comparison method was 89.7% (95% CI, 82.3%-94.3%), the specificity was 48.9% (95% CI, 40.3%-57.5%), and the positive predictive value was 59.8% (Table 3) .
CONCORDANCE OF METHODS
The degree of overall concordance () between the MS method and the RDBH method was 0.945. Both methods detected multiple HPV types in the same 40 samples and single HPV types in the same 175 samples. In 2 samples, the MS method detected multiple types, whereas the RDBH method detected single types. In another 3 samples, the RDBH method detected multiple types, whereas the MS method detected single types. In another 8 samples, the MS method detected single types, whereas the RDBH method detected no HPV.
We compared the efficiencies of type-specific HPV detection by the 2 methods for all samples. Table 4 shows an overview of the number of type-specific infections detected with the 2 methods. For all 502 samples (with 2 ϫ 14 ϫ 502 results), 28 results (0.2%) in 20 samples did not agree between the 2 methods. Fifteen of the 20 discrepant samples were derived from patients with the diagnosis CIN Iϩ. The HPV types missed by RDBH were among 10 patients with a histopathologic or cytologic diagnosis of CIN Iϩ and among 5 patients with no CIN, whereas the HPV types missed by MS were among 9 patients with CIN Iϩ (Table 4 ). In samples with multiple HPV types present, the 2 methods may have had slightly different abilities to detect certain HPV types ( Table 4 ). The MS method alone detected all cases of cancer (Tables 3 and 4 ) and detected HPV 68 in 4 samples. The latter result is in contrast to RDBH, which consistently failed to identify this genotype (Table 4) .
Discussion
Compared with the comparison method and most other reported methods, our new MS-based method had both greater clinical sensitivity for detecting HPV in HPV-associated disease (high-grade CIN IIϩ) and better or comparable analytical sensitivity for the number of HPV copies that could be detected. The use of robotic pipetting and the MS method enables the analysis of 10 ϫ 384 samples within 2 working days, with computerized documentation of sample identity and position at all steps, distinct identification of positive or negative signals by the Sequenom software, and current costs for consumables of about US$2 per sample. By comparison, an analysis of 36 samples by RDBH requires 4 days of labor, and the results depend on a subjective interpretation of dot blots.
Our evaluation was based on a large clinical sample consecutively enrolled from a population-based screening program, suggesting that our results are generally valid with respect to the method's usefulness in a screening setting. An additional strength of the study is Plasmid dilution series generally demonstrated lower detection limits for MS than for the comparison method, with the most notable difference being the greater ability of the MS method to detect HPV type 68. According to a pooled international analysis of HPV type-specific prevalence in 3 085 cervical cancer cases (17 ) , HPV 68 is the 14th most common type in cervical cancer, more common than HPV 66.
The numbers of type-specific HPV infections detected with the 2 methods were almost equal, but the results of the genotyping differed slightly between methods. HPV 33, 52, and 58 (detected more frequently by MS) and HPV 45 (detected more by RDBH) are among the 8 most common types in cervical cancer (18 ) . HPV types 16 and 18 account for about 70% of cervical cancers worldwide (18 ) . In samples positive for multiple HPV types, these genotypes were each detected weakly in 2 samples by RDBH, whereas MS detected other HPV types, suggesting possible crosshybridization. For one of the samples positive for HPV 18 by RDBH, there was a weak HPV 18 peak (below cutoff) in the MS analysis, suggesting a low viral load in the sample. Eight additional results were also both MS negative and RDBH positive, and all originated from samples that were concordant with respect to at least 1 HPV type. All samples that were negative for all 14 genotypes by MS were also negative by RDBH.
In a WHO international collaborative study for the assessment of the performance of various HPVdetection assays (19 ) , a panel of HPV types was analyzed in a number of laboratories, of which half failed to detect 10 000 copies of HPV 31 plasmids. Some laboratories did not detect the same copy numbers of HPV 35 and HPV 52. In the present study, the MS analysis detected 100 copies of HPV 31, 10 copies of HPV 35, and a single copy of HPV 52. The primary PCR primers of the MS method were designed to match some target HPV types better than others. A few primers match their templates perfectly, whereas others contain a minimal number of non-C-A mismatches. Although the detection limit for HPV 31 is slightly higher than for all the other types (except HPV 39) with the MS method, the MS method was generally more sensitive for HPV 31, 35, and 52 than the methods in the WHO study. In general, the number of mismatches is slightly lower with the MS primers than with GP5ϩ/6ϩ primers, but, more importantly, the mismatches are preferentially G-T to optimize thermodynamic stability.
In summary, we have designed a highly automated, potentially high-throughput MS method for the specific detection of 1-100 copies of 14 different oncogenic HPVs in samples of cervical cells. The performance compares well with the comparison method and with other methods reported in the literature. With access to robotic pipetting and the Sequenom system, the MS method allows large-scale HPV genotyping at a low cost, and this method may be useful for cervical screening and to evaluate the effectiveness of HPV vaccination programs via monitoring the circulation of HPV types in vaccinated populations.
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